Noteworthy Ownership Action: Cepheid (NASDAQ:CPHD) Institutional Investors Sentiment

December 1, 2016 - By Louis Casey   ·   0 Comments

Noteworthy Ownership Action: Cepheid (NASDAQ:CPHD) Institutional Investors Sentiment

Sentiment for Cepheid (NASDAQ:CPHD)

Cepheid (NASDAQ:CPHD) institutional sentiment decreased to 0.98 in 2016 Q2. Its down -0.34, from 1.32 in 2016Q1. The ratio dived, as 108 hedge funds increased or started new equity positions, while 82 reduced and sold their positions in Cepheid. The hedge funds in our partner’s database now have: 68.03 million shares, down from 69.27 million shares in 2016Q1. Also, the number of hedge funds holding Cepheid in their top 10 equity positions decreased from 3 to 2 for a decrease of 1. Sold All: 25 Reduced: 57 Increased: 76 New Position: 32.

Cepheid is a molecular diagnostics company. The company has a market cap of $3.87 billion. The Firm develops, makes and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. It currently has negative earnings. The Company’s systems enable molecular testing for organisms and genetic diseases by automating otherwise complex manual laboratory procedures.

It is down 48.61% since April 6, 2016 and is uptrending. It has outperformed by 42.69% the S&P500.

Sandhill Capital Partners Llc holds 3.35% of its portfolio in Cepheid for 348,177 shares. Riverbridge Partners Llc owns 3.68 million shares or 2.35% of their US portfolio. Moreover, Consonance Capital Management Lp has 1.97% invested in the company for 453,662 shares. The Us-based Champlain Investment Partners Llc has invested 1.82% in the stock. 1492 Capital Management Llc, a Wisconsin-based fund reported 56,828 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 insider buys, and 3 insider sales for $43,660 net activity.

Cepheid (NASDAQ:CPHD) Ratings Coverage

Ratings analysis reveals 17% of Cepheid’s analysts are positive. Out of 18 Wall Street analysts rating Cepheid, 3 give it “Buy”, 1 “Sell” rating, while 14 recommend “Hold”. The lowest target is $29 while the high is $72. The stock’s average target of $41.07 is -22.44% below today’s ($52.95) share price. CPHD was included in 43 notes of analysts from July 24, 2015. The firm has “Neutral” rating given on Tuesday, September 6 by Piper Jaffray. The firm earned “Hold” rating on Tuesday, September 6 by Craig Hallum. The rating was maintained by Needham with “Buy” on Friday, July 24. The firm has “Sell” rating given on Friday, July 24 by Evercore. The firm earned “Buy” rating on Friday, April 1 by BTIG Research. The company was initiated on Thursday, November 12 by Stifel Nicolaus. As per Thursday, September 8, the company rating was downgraded by Citigroup. The stock has “Equal Weight” rating given by Barclays Capital on Wednesday, September 2. The company was maintained on Wednesday, October 14 by Needham. The company was downgraded on Wednesday, September 7 by Cowen & Co.

CPHD Company Profile

Cepheid, incorporated on March 4, 1996, is a molecular diagnostics company. The Firm develops, makes and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic diseases by automating otherwise complex manual laboratory procedures. Molecular testing involves various time-intensive steps, including sample preparation, Deoxyribonucleic acid (DNA) amplification and detection. The Company’s systems integrate these steps and analyze biological samples in test cartridges. The Company’s primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. The Firm also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

More notable recent Cepheid (NASDAQ:CPHD) news were published by: Bloomberg.com which released: “Danaher Buys Cepheid for $4 Billion in First Deal Since Spinoff” on September 06, 2016, also Prnewswire.com with their article: “Danaher Completes Acquisition Of Cepheid” published on November 04, 2016, Prnewswire.com published: “Cepheid Announces Receipt of Required Regulatory Clearances in Proposed …” on October 24, 2016. More interesting news about Cepheid (NASDAQ:CPHD) were released by: Prnewswire.com and their article: “Cepheid Announces Expansion Of The Most Comprehensive Molecular C. Difficile …” published on September 15, 2016 as well as Streetinsider.com‘s news article titled: “Danaher (DHR) Announces Completion of Cepheid (CPHD) Acquisition” with publication date: November 07, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>